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Diffuse large B cell lymphoma represents a clinically het-
erogeneous disease, and several immunohistochemical
strategies have been shown to help prognosticate clinical
outcome. These include subdivision into germinal center
(GC) and non-germinal center (non-GC) subtypes, prolif-
eration index (measured by expression of Ki67), and
expression of BCL-2, FOXP1 or Blimp-1/PRDM1. We
sought to determine whether immunohistochemical anal-
yses of biopsies from DLBCL patients with HIV infection
are similarly relevant for prognostication.
We examined 82 DLBCLs from uniformly treated AIDS
patients in AMC 010 (CHOP or CHOP-rituximab) and
AMC 034 (EPOCH-rituximab) clinical trials, and com-
pared the immunophenotype with survival data, Epstein
Barr virus (EBV) positivity and CD4 counts. There was no
significant difference in survival or CD4 counts between
the patients with GC and non-GC subtypes of DLBCL,
regardless of inclusion of rituximab in the treatment regi-
men. EBV assessment showed that this virus can be found
in both subtypes of DLBCL, although less frequently in
the GC subtype, and does not affect survival.
We also evaluated expression FOXP1, which is an inde-
pendent adverse prognostic marker when expressed in
immunocompetent patients with DLBCL, as well as
expression of Blimp-1/PRDM1 and BCL-2. Expression of
FOXP1, Blimp-1/PRDM1 or BCL-2 did not correlate with
the outcome in patients with AIDS-related DLBCL. The
only predictive immunohistochemical marker was found
to be Ki67, where a higher proliferation index was associ-
ated with better survival suggesting a better response to
therapy in patients whose tumors had higher proliferation
rates. These data indicate that with current treatment strat-
egies for lymphoma and control of HIV infection, com-
monly used immunohistochemical markers may not be
clinically relevant in HIV-infected DLBCL patients.
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